Following development by a working group of healthcare professionals from Manchester and Trafford, we now seek comments on the draft document: ‘DOAC switch to edoxaban for NVAF patients – protocol’.

All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.

Update 02/10/2023: this consultation has been paused following the updated tariff price for apixaban. Comments will be held and will not need to be re-submitted if the consultation re-opens.

Please note

  1. The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to
  2. This consultation initially ran for three weeks and was expected to close at 5pm on Monday 9th October 2023. It is now paused.